RICHMOND, Va.--(BUSINESS WIRE)--Insmed, Inc. (NASDAQ: INSM) announced results of its recent series of stability studies for IPLEX™, the company’s once-daily treatment for children with short stature associated with severe primary IGF-I deficiency. Study results were presented at the Growth Hormone Research Society/IGF Society meeting in Kobe, Japan, Nov. 11-15.
